Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Medical Life Care Planners, LLC
Modality
Small molecule
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05574049CT.gov Weight Loss, Blood Sugar and Blood Lipid Effects of Tetrahydrocannabivarin (THCV) Impregnated Mucoadhesive Strips | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hyperglycemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cannabivarol, .Delta.9-Tetrahydro- (this asset) | Medical Life Care Planners, LLC | Early P1 | CC · 43 |
| Metformin | The First Affiliated Hospital of Xiamen University | P4 | BBB |
| Olanzapine | Washington University School of Medicine | P4 | BB |
| Exenatide | Saint Luke's Health System | P4 | BB |
| Sitagliptin | Dawn Smiley MD | P4 | BB |
| Saffron | Birjand University of Medical Sciences | P4 | BB |
| Capecitabine | Brigham and Women's Hospital | P4 | BB |
| Risperidone | Nathan Kline Institute for Psychiatric Research | P4 | BB |
| Losartan | Brigham and Women's Hospital | P4 | BB |
+26 more in the Hyperglycemia cohort
Other indications for Cannabivarol, .Delta.9-Tetrahydro-
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Morbid Obesity | — | Early P1 | CC · 41 |
| Abdominal Obesity-Metabolic Syndrome | — | Early P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cannabivarol, .Delta.9-Tetrahydro- in Hyperglycemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cannabivarol-delta9-tetrahydro-hyperglycemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →